Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|January 20, 2011
Update of the drug resistance mutations in HIV-1: December 2010Victoria A Johnson, Françoise Brun-Vézinet, Bonaventura Clotet, et al.Topics in HIV Medicine : a Publication of the International AIDS Society, USA|November 24, 2005
Update of the drug resistance mutations in HIV-1: Fall 2005Victoria A Johnson, Francoise Brun-Vezinet, Bonaventura Clotet, et al.AIDS Research and Human Retroviruses|May 18, 2019
Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210Victoria A Johnson, Yoninah S Cramer, Susan L Rosenkranz, et al.Antiviral Therapy|October 12, 2007
Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapyJeff D Moore, Edward P Acosta, Victoria A Johnson, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2004
Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuationJoseph J Eron, John A Bartlett, Jorge L Santana, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 25, 2014
Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227Mary A Vogler, Laura M Smeaton, Rodney L Wright, et al.The Journal of Infectious Diseases|September 18, 2013
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b studyMark S Sulkowski, Minhee Kang, Roy Matining, et al.Topics in HIV Medicine : a Publication of the International AIDS Society, USA|January 16, 2004
Drug resistance mutations in HIV-1Victoria A Johnson, Françoise Brun-Vézinet, Bonaventura Clotet, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 6, 2009
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjectsGail Skowron, John G Spritzler, Jodi Weidler, et al.Journal of Clinical Microbiology|June 12, 2015
Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay SensitivityChristina M Lalama, Cheryl Jennings, Victoria A Johnson, et al.Pageof 6